Organon & Co. Common Stock (NY:OGN)

Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.

Topics Fraud

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗

March 20, 2026

Via The Motley Fool

3 Value Stocks We Approach with Caution

March 20, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re barga...

Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook ↗

February 12, 2026

Via Chartmill

Topics Earnings

1 Stock Under $10 to Own for Decades and 2 That Underwhelm

March 19, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

3 of Wall Street’s Favorite Stocks We Approach with Caution

March 13, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

3 Small-Cap Stocks We Approach with Caution

March 04, 2026

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

February 27, 2026

The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy

February 26, 2026

As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the...

Via Finterra

Topics Economy

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

February 23, 2026

Organon's fourth quarter was met with a negative market reaction as operational challenges and shifting demand patterns weighed on results. Management pointed to continued pricing pressure, loss of...

5 Revealing Analyst Questions From Organon’s Q4 Earnings Call

February 19, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Topics Earnings

Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know

February 13, 2026

Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5.3% year on year to $1.51 billion. The company’s full-year revenue guidance of $6.2...

Topics Economy

OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook

February 13, 2026

Organon (OGN) Q4 2025 Earnings Call Transcript

Organon (OGN) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Via The Motley Fool

Topics Earnings

Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations

February 12, 2026

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

February 12, 2026

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know.

Organon Earnings: What To Look For From OGN

February 10, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

Topics Artificial Intelligence World Trade

2 Healthcare Stocks with Promising Prospects and 1 We Brush Off

February 04, 2026

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Topics Stocks

January 29, 2026

Organon Completes Divestiture of JADA® System to Laborie

January 28, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Nasdaq, S&P 500 Futures Rise As Trump Diffuses Tariff Risk: Why INTC, MSFT, NFLX, RKLB, OGN Are On Traders' Radar Today ↗

January 22, 2026

Retail sentiment on Stocktwits for SPY and QQQ remains ‘bearish,’ signaling caution.

Via Stocktwits

Topics ETFs Earnings Economy

Why Are Organon (OGN) Shares Soaring Today

January 20, 2026

Shares of pharmaceutical company Organon (NYSE:OGN) jumped 8.9% in the afternoon session after reports surfaced that Sun Pharmaceutical Industries submitted a non-binding proposal to acquire the...

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Topics Artificial Intelligence Initial Public Offering Supply Chain

January 16, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

3 Small-Cap Stocks We Approach with Caution

January 07, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have...

3 Healthcare Stocks with Questionable Fundamentals

December 15, 2025

Shares of pharmaceutical company Organon (NYSE:OGN) fell 4.7% in the afternoon session after Barclays initiated coverage on the company with an 'Underweight' rating and a price target of $7.50. The new...

Topics Stocks

Why Organon (OGN) Shares Are Trading Lower Today

December 09, 2025

Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be...

Topics Initial Public Offering

3 Stocks Under $10 We Steer Clear Of

December 08, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

3 Value Stocks with Questionable Fundamentals

December 04, 2025